NCT07748091Recruiting
EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT
The Relationship of EEG Microstate Parameters and Neuroinflammatory Biomarkers With Treatment Response in Patients With Treatment-Resistant Major Depressive Disorder Receiving Electroconvulsive Therapy
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant treatments, using microstate analysis derived from resting-state electroencephalography (EEG) recordings. Within this scope, EEG recordings obtained before and after ECT will be compared to determine the relationships between changes in microstate parameters and inflammatory marker levels, clinical variables, and psychometric scale scores reflecting clinical improvement. Peripheral blood samples collected from the same patient group will be analyzed for complete blood count parameters as well as levels of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), soluble glycoprotein 130 (sgp-130), soluble interleukin-6 receptor (sIL-6R), interferon gamma-induced protein 10 kDa (IP-10), and C-reactive protein (CRP). In addition, inflammatory indices, including the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR), will be calculated. The association between baseline levels of these biomarkers and treatment response will be evaluated. Moreover, changes in biomarker levels following ECT will be statistically examined in relation to clinical scale scores and EEG microstate parameters. Although microstate analysis and inflammatory biomarkers have each been extensively investigated in psychiatric disorders, studies evaluating these two biomarkers together, particularly with the inclusion of healthy control participants, remain limited. In this regard, the present study aims to evaluate the effects of ECT on patients with treatment-resistant depression using objective neurophysiological indicators, to contribute to the understanding of the pathophysiology of depression at the level of brain networks, and to provide a scientific basis for the development of personalized treatment approaches in the future.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 62 (estimated)
- First submitted
- 5 Jul 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Istanbul University - Cerrahpasa
- Diseases
- Depression
- NCT number
- NCT07748091
What you commit to
- Study type: Observational
- Planned participants: 62
- From 1 Jan 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Myocardial infarction within the previous 3 months.
- Cerebrovascular disease within the previous month.
- Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month.
- Current use of systemic corticosteroids, immunosuppressive agents, or other medications known to affect inflammatory biomarkers significantly.
Other illness
- Primary neurological disorders (e.g., dementia or traumatic brain injury).
- Schizophrenia or other psychotic disorders.
- Bipolar disorder diagnosis,
- Cognitive impairment severe enough to prevent adequate cooperation during EEG recording.
- Current alcohol or substance use disorder.
- Active infectious disease.
- Autoimmune or chronic inflammatory disorders.
Other
- Intracranial space-occupying lesions.
- Increased intracranial pressure.
- Unstable cerebral aneurysm.
- Pheochromocytoma.
Who the study is looking for
- Patient Group
- Age 18-60 years
- Diagnosis of Major Depressive Disorder, current major depressive episode, according to DSM-5 criteria.
- Clinical indication for electroconvulsive therapy (ECT).
- Ability to provide written informed consent.
- Willingness to participate in the study.
- Healthy Control Group:
- Age ≥55 years.
- No current psychiatric disorder.
- No known neurological disorder.
- Good general physical health.
- No current use of medications known to affect EEG activity or inflammatory biomarkers significantly.
- Ability to provide written informed consent.
- Willingness to participate in the study.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| İstanbul University- Cerrahpasa, Cerrahpasa Medicine Faculty, Psychiatry Department Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.